Bad news for income trusts

Bad news. Last week we wrote about the dismal performance of Temple Bar, one of the constituents of our model investment trust portfolio. We also said that we weren’t dropping it (for now). Yes, the trust went into this crisis very well positioned for a surge in value stocks – but extremely badly positioned for a pandemic that favoured the business models of seemingly overpriced growth stocks. And yes, it is still down 46% in the last three months – double that of the average equity income trust. However, we have long had great respect for Temple Bar’s manager Alastair Mundy’s well-established contrarian approach (which is why we chose the trust in the first place) and we felt we should wait to see how the next few months went before abandoning his process. 

Sadly as with everything these days, events have moved faster than expected. Mundy has now stood down on health grounds and Temple Bar’s board is wondering what to do next. So that, I am afraid, is that. We will take it out of the portfolio. Possible replacements are Troy Growth & Income (but Personal Assets, which we also hold, has the same management company, which might be style overkill for us); Aurora Investment Trust (which takes a contrarian value approach a little like Mundy’s – and is down 35% in three months); Dunedin Income Growth, or perhaps (to give us more of a global income) JP Morgan Global Growth & Income. Otherwise I wonder if it is time to add a Japanese fund to the mix – particularly given that we are replacing what was an income generator and Japanese dividends seem safer than most. Opinions on this are welcome – send your thoughts to editor@moneyweek.com below and we will decide over the next week.

The best investment you can make today

In this week's magazine, Matthew Lynn has some thoughts on the future of income trusts as well (none of them good, I’m afraid). David Stevenson has been looking at the sector too. If you didn’t buy a few weeks ago you may have missed your chance to get great trusts at amazing discounts – but even now, says David, there are a few nice opportunities knocking around if you have cash you feel ready to invest (bearing in mind the thought that the bear market may be far from over ). 

You might think we are better off focusing on a Covid-19 cure than prevention in the short term, but nonetheless the firm that wins the vaccine race will definitely turn out to have been worth holding. Maybe hold shares in some of the main players in the world of vaccines, which Matthew Partridge  looks at this week. And Michael Taylor looks at some of the most interesting stocks listed on Aim for brave investors to consider. 

Finally a note on the best investment you can make today – start work on getting appointed to the House of Lords. Half a million or so spent on good works of one kind of another plus a good bit of grandstanding about it could get you in (I accept there is risk here – could be more, could be less). Once you’re in, you get a tax-free “allowance” of £48,000 a year, effectively inflation-linked (assuming you turn up 150 days a year – although self-isolating peers are now agitating to get the cash if they appear by video link too). Your capital will be lost of course, but a net 10% a year return? Not bad. I’m only half joking.